This review highlights the evolving management of cardiorenal syndrome in HFpEF, emphasizing the potential of novel biomarkers and therapies like renal denervation and interatrial shunts.
Answers are grounded in this paper and cite their sources.
Should not change practice in cardiorenal HFpEF; leaves open the role of novel biomarkers and therapies pending trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Khandait et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: